SAN FRANCISCO, Sept. 14, 2022 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. NRIX, a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Edward C. Saltzman to its board of directors. Mr. Saltzman has over 30 years of strategic drug development experience in the biopharmaceutical and biotechnology industries and is currently Head of Biotechnology Strategy at Lumanity Inc., a global pharmaceutical and biotechnology consulting firm.
“I am delighted to welcome Ed to the Nurix Board of Directors at this important stage in the company’s growth as we advance multiple programs through clinical trials with significant potential to treat cancer patients,” said Arthur T. Sands, MD, Ph. D ., President and Chief Executive Officer of Nurix. “The entire Nurix team will benefit from Ed’s significant industry expertise and strategic development experience as our innovative science continues to generate promising new drug candidates.”
Mr. Saltzman commented, “Nurix is a leader in the development of novel small molecules to modulate protein levels in cells and is initially developing these innovative drugs as potential therapies to treat hematological and solid tumors. I am excited about the broad potential of the Nurix DELigase platform and very excited to join the company’s Board of Directors. I look forward to working with the leadership team to help achieve Nurix’s mission of bringing novel therapies to patients in need.”
Mr. Saltzman has been Head of Biotech Strategy at Lumanity since March 2022. In 1993, Mr. Saltzman founded Defined Health Inc., a wealth development strategy consulting firm, and has led it to become a premier advisor to the senior management and boards of biotechnology and biopharmaceutical companies, including those developing novel drug discovery platforms. Following the sale of Defined Health to Cello Health plc in January 2017, Mr. Saltzman…
